var data={"title":"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/contributors\" class=\"contributor contributor_credentials\">Denise W Metry, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 24, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vascular lesions of infants and children are classified into two major types: tumors and vascular malformations [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/1\" class=\"abstract_t\">1</a>]. Infantile hemangiomas are the most common vascular tumors [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/2\" class=\"abstract_t\">2</a>]. Other examples of vascular tumors include pyogenic granuloma, kaposiform hemangioendothelioma, and tufted angioma. So-called rapidly involuting (RICH) and non-involuting (NICH) &quot;congenital&quot; hemangiomas appear histopathologically to be hybrids showing features of both vascular tumor and malformation. Because cases of RICH evolving into NICH have been reported, it has been suggested that these two entities lie within the same spectrum [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/3,4\" class=\"abstract_t\">3,4</a>].</p><p>Infantile hemangiomas are characterized by a growth phase and an involution phase. In contrast, vascular malformations, which are structural anomalies derived from capillaries, arteries, veins, lymphatics, or a combination thereof, grow in proportion to the child but generally do not regress. Vascular malformations are discussed separately. (See <a href=\"topic.htm?path=vascular-lesions-in-the-newborn\" class=\"medical medical_review\">&quot;Vascular lesions in the newborn&quot;</a> and <a href=\"topic.htm?path=venous-malformations\" class=\"medical medical_review\">&quot;Venous malformations&quot;</a> and <a href=\"topic.htm?path=klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management&quot;</a> and <a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">&quot;Capillary malformations (port wine stains) and associated syndromes&quot;</a>.)</p><p>Despite their benign and self-limited nature, some hemangiomas can cause complications such as ulceration and permanent disfigurement. In addition, some may compromise vital organ function or herald underlying developmental anomalies of the spine, central nervous system, circulatory system, <span class=\"nowrap\">and/or</span> eyes. Hemangiomas in the liver, brain, or gastrointestinal tract may rarely cause life-threatening complications. Large size, facial location, <span class=\"nowrap\">and/or</span> segmental morphology are the most common predictors of poor short-term outcomes as measured by complication and treatment rates [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H9\" class=\"local\">'Segmental lesions'</a> below.)</p><p>An overview of the epidemiology, pathogenesis, clinical features, and complications of infantile hemangiomas will be presented here. The evaluation and management are discussed separately. (See <a href=\"topic.htm?path=infantile-hemangiomas-evaluation-and-diagnosis\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Evaluation and diagnosis&quot;</a> and <a href=\"topic.htm?path=infantile-hemangiomas-management\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemangiomas are the most common tumors of infancy. The true incidence of infantile hemangiomas is unknown [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/6\" class=\"abstract_t\">6</a>]. Although they are classically said to occur in up to 10 percent of Caucasian infants [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/7,8\" class=\"abstract_t\">7,8</a>], 4 to 5 percent is probably a better estimate [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/6,9\" class=\"abstract_t\">6,9</a>]. Infantile hemangiomas are generally noticed within the first few days to months of life [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/10,11\" class=\"abstract_t\">10,11</a>]. Although most hemangiomas occur sporadically, familial transmission in an autosomal dominant fashion has been reported [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/12\" class=\"abstract_t\">12</a>]. In one series of 136 <span class=\"nowrap\">patients/families,</span> 34 percent had a family history of infantile hemangiomas, most often in first-degree relatives [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas are two to three times more common among females than males [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/14-16\" class=\"abstract_t\">14-16</a>]. Complicated hemangiomas are even more likely to occur among female infants, for reasons that are unknown [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas are more common among white non-Hispanic infants than other racial groups [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/7,16,18\" class=\"abstract_t\">7,16,18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The incidence of hemangiomas is increased in preterm infants [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/16\" class=\"abstract_t\">16</a>]; the most significant risk factor appears to be low birth weight.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple hemangiomas more commonly occur in products of multiple gestations [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prenatal associations include older maternal age, placenta previa, pre-eclampsia, and other placental anomalies [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/9,16\" class=\"abstract_t\">9,16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chorionic villus sampling does not appear to play a significant role in the formation of most hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemangiomas are characterized by phases of proliferation and involution as defined by a rapid proliferation of blood vessels in the first year of life, followed by gradual regression of the vascular component with replacement by fibrofatty tissue. The exact mechanisms that govern these processes are incompletely understood but are beginning to be elucidated. </p><p>Multiple lines of evidence suggest that hypoxia may have a key role in the pathogenesis of hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/19,20\" class=\"abstract_t\">19,20</a>]. They include epidemiologic data on the association of infantile hemangiomas with conditions related with placental hypoxia (eg, low birthweight, retinopathy of prematurity, multiple pregnancies, placental anomalies) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/9,16\" class=\"abstract_t\">9,16</a>] and the demonstration in proliferating hemangiomas of multiple targets of hypoxia inducible factor-1-alpha, such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/21\" class=\"abstract_t\">21</a>]. It has been proposed that in utero hypoxia or local hypoxia may be the initiating factor for the development of hemangiomas, with the proliferating phase being a homeostatic attempt to normalize the hypoxic tissue [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/22\" class=\"abstract_t\">22</a>].</p><p>GLUT1 and placenta-associated vascular antigens (Fc-gamma-receptor II, merosin, and Lewis Y antigen) are highly expressed in the endothelial cells of infantile hemangiomas during both the proliferative and involution phase [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/23-25\" class=\"abstract_t\">23-25</a>]. These markers are not expressed in normal dermal or subcutaneous capillaries, nor are they expressed in other types of vascular tumors. The only other vasculature known to share this constellation of markers is that of placental chorionic villi. The gene expression profiles of hemangiomas and placenta are very similar compared with other tissue, suggesting that they share a common genetic program [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/26\" class=\"abstract_t\">26</a>]. However, the precise relationship between infantile hemangiomas and chorionic villi has yet to be explained.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Proliferation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although biopsy of hemangiomas is not routinely necessary because the diagnosis can generally be made clinically, histologic examination during the proliferation stage demonstrates superficial proliferating angioblastic endothelial cells with few capillary lumina [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Current evidence suggests that hemangiomas are clonal proliferations of endothelial cells [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/28,29\" class=\"abstract_t\">28,29</a>], resulting from vasculogenesis (the formation of primitive blood vessels from angioblasts), rather than angiogenesis (the growth of new vessels from pre-existing vessels) as traditionally thought [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/30\" class=\"abstract_t\">30</a>]. This hypothesis is supported by a study in which implantation of multipotential stem cells from human hemangioma tissue (isolated based on expression of CD133, a stem cell population marker) gave rise to hemangioma-like lesions in immunodeficient mice that spontaneously regressed, similar to what occurs in infantile hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/31\" class=\"abstract_t\">31</a>].</p><p>In addition, proliferating hemangiomas contain hematopoietic leukocytes of myeloid origin that may play a role in hemangioma growth. Hemangioma endothelial cell coexpression of myeloid markers CD83, CD32, CD14, and CD15 supports the concept that hemangioma endothelium is distinct from that of normal vasculature [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/32\" class=\"abstract_t\">32</a>].</p><p>Hemangioma proliferation appears to result from an imbalance between positive and negative vasculogenic factors expressed by the hemangioma and adjacent normal tissue [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/33\" class=\"abstract_t\">33</a>]. This is supported by the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased expression of endothelial cell markers (eg, CD34 and CD31), primitive cell population markers (eg, CD133 and LYVE-1 [a marker for lymphatic vessels]), IGF-2, and certain integrins in proliferating hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/21,34-36\" class=\"abstract_t\">21,34-36</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Overexpression of basic fibroblast growth factor (bFGF, FGF 2), VEGF, proliferating cell nuclear antigen, and type IV collagenase in proliferating hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/33,37,38\" class=\"abstract_t\">33,37,38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infantile hemangioma has suppressed VEGF receptor 1 (VEGFR1) expression, but constitutive VEGF receptor 2 (VEGFR2) signaling, an effect mediated by nuclear factor of activated T cells (NFAT), and mutations in VEGFR2 or the integrin-like receptor TEM-8 have been found in some individuals with hemangiomas that inhibit the activity of NFAT pathway [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Imbalance of two VEGF receptor tyrosine kinases (VEGFR1 and VEGFR2) affected availability of VEGF and endothelial cell proliferation in hemangioma-derived endothelial cells (<a href=\"image.htm?imageKey=PEDS%2F64171\" class=\"graphic graphic_figure graphicRef64171 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/39,40\" class=\"abstract_t\">39,40</a>]. Treatment of the cell lines with VEGF neutralizing antibodies normalized the VEGF signaling profile.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased quantities of bFGF and matrix metalloproteinases in the urine of patients with proliferating hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/37,41\" class=\"abstract_t\">37,41</a>].</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Involution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The spontaneous involution phase typically begins in the late part of the first year and continues over a variable number of years. Involution is characterized by histologic fibrosis of capillary lumina. Increased apoptosis during the second year appears to counteract proliferation and may be involved in initiating involution [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/42\" class=\"abstract_t\">42</a>]. This is supported by the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased numbers of mast cells and levels of tissue metalloproteinase (an inhibitor of new blood vessel formation) in involuting hemangiomas.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Upregulation of interferon-induced genes in involuting hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/32\" class=\"abstract_t\">32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreased quantities of bFGF in the urine of patients with involuting hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/37,43\" class=\"abstract_t\">37,43</a>].</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of hemangiomas are not clinically evident at birth but become apparent within the first days to months of life [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/15,44\" class=\"abstract_t\">15,44</a>]. Some newborns have a premonitory cutaneous mark, such as a patch of telangiectasias with surrounding pallor (secondary to vasoconstriction) at the hemangioma site (<a href=\"image.htm?imageKey=DERM%2F89391\" class=\"graphic graphic_picture graphicRef89391 \">picture 1</a>). Early lesions may be so subtle as to go unrecognized and may be mistaken for a scratch or bruise. Less commonly, a hemangioma may appear initially as a bright red patch resembling a port-wine stain.</p><p>The majority of lesions are solitary, but multiple lesions occur in up to 20 percent of infants and are especially common among multiple births [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/15\" class=\"abstract_t\">15</a>]. Hemangiomas have a predilection for the head and neck, although they can occur anywhere in the skin, mucous membranes, or internal organs. Hemangiomas range in size from a few millimeters to many centimeters in diameter. They may be superficial, deep, or combined (compound hemangioma).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The superficial presentation is most common [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/45\" class=\"abstract_t\">45</a>] and consists of a bright red papule, nodule, or plaque raised above clinically normal skin (<a href=\"image.htm?imageKey=PEDS%2F60004\" class=\"graphic graphic_picture graphicRef60004 \">picture 2</a>). Superficial hemangiomas have been called &quot;strawberry&quot; or &quot;capillary&quot; hemangiomas, but superficial hemangioma is the preferred term [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/46\" class=\"abstract_t\">46</a>], since not all superficial hemangiomas have the &quot;strawberry&quot; appearance, and not all strawberry-like lesions are hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/47,48\" class=\"abstract_t\">47,48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The deep, or subcutaneous, hemangioma is typically a raised, skin-colored nodule, which often has a bluish hue with or without central telangiectatic patch (<a href=\"image.htm?imageKey=PEDS%2F50388\" class=\"graphic graphic_picture graphicRef50388 \">picture 3</a>). Purely deep hemangiomas are less common [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/45\" class=\"abstract_t\">45</a>]. They have been called &quot;cavernous&quot; hemangiomas, a term that is also erroneously used to describe venous malformations and thus is best avoided.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Combined hemangiomas are fairly common and contain both superficial and deep components [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/45\" class=\"abstract_t\">45</a>].</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Natural history</span></p><p class=\"headingAnchor\" id=\"H5833753\"><span class=\"h3\">Proliferation and involution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemangiomas characteristically undergo a growth (proliferative) phase that is generally rapid for the first several months. Slow proliferation can continue for the first 6 to 12 months [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/49,50\" class=\"abstract_t\">49,50</a>]. Proliferation after the first year can occur but is uncommon [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/3,50\" class=\"abstract_t\">3,50</a>].</p><p>The growth characteristics of 526 infantile hemangiomas were described in a multicenter, longitudinal, cohort study of 433 children who were followed by pediatric dermatologists in tertiary care centers [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/50\" class=\"abstract_t\">50</a>]. In this referral population:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The largest increase in size occurred during the early proliferative stage; by five months of age, the average hemangioma had already achieved 80 percent of its final size, with the most rapid growth occurring within the first three months of age.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The late proliferative stage (ongoing, but less rapid growth) was usually complete by nine months of age; only 3 percent of lesions had documented growth after nine months of age. Deep hemangiomas tended to appear and grow later and longer than superficial hemangiomas.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas proliferated within a defined anatomic area; increased volume was achieved without centrifugal spread.</p><p/><p>In a small prospective study including 30 infants, serial images were analyzed to evaluate the hemangioma growth rate. Photographs were taken at intervals of one to two weeks starting one to two weeks after birth [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/51\" class=\"abstract_t\">51</a>]. The study found that hemangioma growth is nonlinear and that the most rapid growth takes place between 5.5 and 7.5 weeks of age.</p><p>The proliferative phase is followed by a spontaneous involution phase that typically begins after one year and lasts a variable number of years [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/50\" class=\"abstract_t\">50</a>]. Superficial hemangiomas typically enter the involution stage earlier than deep hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/50\" class=\"abstract_t\">50</a>].</p><p>The first clinical sign of involution within a superficial hemangioma is a color change from bright red to dark or violaceous red to gray, which often begins centrally as the tumor softens and flattens [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/15,50\" class=\"abstract_t\">15,50</a>]. An early white discoloration of the hemangioma surface occurring in infants younger than three months may herald ulceration, not involution [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/52\" class=\"abstract_t\">52</a>]. Deep lesions become less blue and warm. The rate and extent of hemangioma involution varies among affected children and may be proportional to size, with larger lesions exhibiting longer periods of growth and involution and smaller lesions shorter periods of growth and involution [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Completed involution occurs at an estimated minimum rate of 10 percent per year, so approximately 50 percent of hemangiomas have involuted by age five years, 70 percent by age seven, and 90 percent by age nine. However, the rate of involution is highly variable. It also must be emphasized that in many cases, complete involution does not result in normal-appearing skin. Up to one-half of children with hemangiomas experience residual changes such as scarring, atrophy, redundant skin, discoloration, and telangiectasias. Clinicians who evaluate children who have hemangiomas should be realistic with parents about the potential outcomes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Superficial, very raised hemangiomas, especially those that exhibit a sharp, &quot;cliff-like'&quot; border (<a href=\"image.htm?imageKey=DERM%2F61868\" class=\"graphic graphic_picture graphicRef61868 \">picture 4</a>), or pedunculated lesions (hemangiomas extending from a smaller base) are at risk for residual fibrofatty tissue, which may ultimately require surgical intervention.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas of the lip that cross the vermillion border (<a href=\"image.htm?imageKey=PEDS%2F60003\" class=\"graphic graphic_picture graphicRef60003 \">picture 5</a>) and large tumors of the nose (&quot;Cyrano nose&quot;) and auricle are more prone to disfigurement.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Large tumor or plaque-like lesions, especially when rapidly proliferating <span class=\"nowrap\">and/or</span> in trauma-prone locations, show a tendency toward ulceration, which invariably leads to scarring.</p><p/><p class=\"headingAnchor\" id=\"H3163479\"><span class=\"h3\">Infantile hemangiomas with minimal or arrested growth</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In a minority of cases, hemangiomas fail to proliferate beyond the telangiectatic patch associated with the premonitory stage or only a small portion of the lesion proliferates (<a href=\"image.htm?imageKey=DERM%2F65721\" class=\"graphic graphic_picture graphicRef65721 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/53,54\" class=\"abstract_t\">53,54</a>]. The majority of these hemangiomas occur on the lower body and also show a tendency toward acral locations. (See <a href=\"#H83438641\" class=\"local\">'Acral lesions'</a> below.) </p><p>Infantile hemangiomas with minimal or arrested growth are often confused with port-wine stains; a blotchy red-blue patch with perilesional blanching and both fine and coarse telangiectasias suggests a diagnosis of hemangioma [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/53\" class=\"abstract_t\">53</a>]. A small proliferative component, often at the lesion periphery, is another useful diagnostic clue. However, a proliferative component is present in less than one-third of cases.</p><p>Additional studies are necessary to determine the natural history of this variant.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Localized lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemangioma morphology provides an important clue to potential complications [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/14\" class=\"abstract_t\">14</a>]. Hemangiomas can be categorized as localized (or focal), segmental, or multiple. (See <a href=\"#H15\" class=\"local\">'Complications'</a> below.)</p><p>Localized hemangiomas, which constitute the majority of lesions, demonstrate clear, well-defined spatial containment, appear to arise from a single focus, and lack evidence of a linear or geometric pattern. Localized hemangiomas of the face appear to occur near lines of mesenchymal or mesenchymal-ectodermal embryonic fusion.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Segmental lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Segmental hemangiomas are usually patch or plaque-like and demonstrate a linear <span class=\"nowrap\">and/or</span> geographic presence over a specific cutaneous territory (<a href=\"image.htm?imageKey=PEDS%2F82212\" class=\"graphic graphic_picture graphicRef82212 \">picture 7</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/14,55\" class=\"abstract_t\">14,55</a>]. In one study, photographs of 165 patients with segmental or indeterminate facial hemangiomas were analyzed [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/55\" class=\"abstract_t\">55</a>]. Four distinct patterns of involvement were identified (segments 1 to 4). Segments 2 and 3 corresponded to the maxillary and mandibular previously described [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/56\" class=\"abstract_t\">56</a>]. However, segment 1 involves the lateral forehead, anterior temporal scalp, and lateral frontal scalp, and segment 4 involves the medial frontal scalp, nose, and philtrum. These observations suggest that neural crest derivatives may be involved in facial hemangioma development.</p><p>Segmental hemangiomas are more likely to occur among female infants and, compared with localized lesions, are much more likely to be associated with complications [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/14,57\" class=\"abstract_t\">14,57</a>]. Children with segmental hemangiomas generally require more intensive and prolonged therapy and have a poorer overall outcome than children with hemangiomas of localized morphology [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">PHACE syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PHACE syndrome (MIM 606519) is a neurovascular syndrome defined by the presence of a large, segmental hemangioma, usually on the face or head, in association with one or more congenital malformations, most commonly structural or cerebrovascular anomalies of the brain (<a href=\"image.htm?imageKey=PEDS%2F80245\" class=\"graphic graphic_table graphicRef80245 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/58-60\" class=\"abstract_t\">58-60</a>]. The syndrome represents a spectrum of disease, with few infants manifesting the entire constellation of anomalies. An expert panel met to develop consensus criteria for PHACE syndrome and possible PHACE syndrome [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/60\" class=\"abstract_t\">60</a>]. Diagnosis of PHACE requires clinical examination of the skin and eyes, as well as imaging of the head, neck, and chest [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/57\" class=\"abstract_t\">57</a>].</p><p>PHACE is not rare; one study suggests that it may be more common than Sturge-Weber syndrome [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/61\" class=\"abstract_t\">61</a>]. It is more common among girls than boys, with an 8 to 9:1 ratio [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/57\" class=\"abstract_t\">57</a>]. Most cases occur in full-term, normal-birth-weight, singleton infants. This is in contrast to non-PHACE hemangiomas, which have an increased incidence in preterm, low-birth-weight infants and in products of multiple gestations [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p>In addition to the varied spectrum, the general ipsilateral relationship between the cutaneous hemangioma and associated anomalies in patients with PHACE suggests a defect involved in lateralization or &quot;developmental field defect,&quot; which implies that certain insults of embryonic development at a specific critical time may give rise to very similar developmental outcomes [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/57,62\" class=\"abstract_t\">57,62</a>]. The type of structural anomalies found in association with PHACE suggests that the timing of these errors in morphogenesis occurs early, probably between 3 and 12 weeks of gestation, prior to or during early vasculogenesis [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/63\" class=\"abstract_t\">63</a>].</p><p>The hallmark of PHACE syndrome, a large, segmental hemangioma, usually on the face, may involve one to several facial dermatomes (<a href=\"image.htm?imageKey=DERM%2F70599\" class=\"graphic graphic_picture graphicRef70599 \">picture 8</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/59,64\" class=\"abstract_t\">59,64</a>]. In one prospective study of 108 infants with large facial hemangiomas (&ge;22 cm<sup>2</sup>), 33 (31 percent) had PHACE syndrome [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/65\" class=\"abstract_t\">65</a>]. An early presentation may be mistaken for the port wine stain associated with the Sturge-Weber syndrome. However, a port wine stain is a vascular malformation that, unlike infantile hemangioma, does not proliferate in infancy or regress.</p><p>Cerebral vascular anomalies appear to be the most common extracutaneous manifestation of PHACE. Structural and cerebrovascular brain malformations occur in the vast majority of patients [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/57\" class=\"abstract_t\">57</a>]. Posterior fossa malformations, including the Dandy-Walker complex, cerebellar hypoplasia or atrophy, <span class=\"nowrap\">and/or</span> <span class=\"nowrap\">dysgenesis/agenesis</span> of the vermis, are the most common structural brain anomalies [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/61,66,67\" class=\"abstract_t\">61,66,67</a>]. These structural anomalies may be associated with developmental delays, particularly motor delays, and pituitary dysfunction [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/68\" class=\"abstract_t\">68</a>]. The cerebrovascular anomalies, especially carotid artery anomalies, are of particular concern because of reports of progressive arterial occlusion, stroke, and other neurologic complications during infancy and childhood [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/63,69-72\" class=\"abstract_t\">63,69-72</a>].</p><p>Cardiac anomalies are the second most common extracutaneous manifestation of PHACE, and include coarctation of the aorta, complex aortic arch anomalies, and ventricular and atrial septal defects, among others [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/58,64\" class=\"abstract_t\">58,64</a>]. The aortic coarctation observed in PHACE differs from classic coarctation in that it is more proximal (often involving the arteries feeding the upper extremities) and involves longer segments, which may preclude detection based upon a blood pressure gradient between the upper and lower extremities [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/57\" class=\"abstract_t\">57</a>].</p><p>Ophthalmologic anomalies are much less common but may include microphthalmos, retinal vascular abnormalities or persistent fetal retinal vessels, optic nerve atrophy, iris hypertrophy or hypoplasia, exophthalmos, colobomas (fissure or cleft of the iris, ciliary body, or choroid), and excavated optic disc anomalies (including &quot;morning glory&quot;), among others [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/73\" class=\"abstract_t\">73</a>]. </p><p>Ventral developmental defects include sternal clefting (ranging from a sternal pit, without underlying soft tissue or bony loss, to complete separation of the sternal bars) or the presence of a supraumbilical raphe, which resembles a well-healed scar extending superiorly from the umbilicus [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/64\" class=\"abstract_t\">64</a>].</p><p>Endocrinologic abnormalities have been reported in a small number of patients [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/68\" class=\"abstract_t\">68</a>]. The endocrine abnormalities can be easily overlooked, and a low threshold of suspicion must be maintained [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/57\" class=\"abstract_t\">57</a>]. </p><p>Swallowing dysfunction and speech and language delay have been reported in children with PHACE syndrome, particularly those with structural brain anomalies [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/74\" class=\"abstract_t\">74</a>]. Tooth enamel hypoplasia has been observed in patients with intraoral hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/75\" class=\"abstract_t\">75</a>]. Hearing loss (conductive or sensorineural) may also occur in patients with PHACE syndrome, particularly when the associated segmental hemangioma extends over the scalp to surround and involve the ear [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/76\" class=\"abstract_t\">76</a>]. Early onset of migraine-like headache has been reported in over 60 percent of patients with PHACE syndrome [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/77\" class=\"abstract_t\">77</a>]. (See <a href=\"topic.htm?path=infantile-hemangiomas-evaluation-and-diagnosis#H13165020\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Evaluation and diagnosis&quot;, section on 'PHACE syndrome'</a>.)</p><p>A PHACE registry has been established to promote further understanding of this disorder. Information about the registry may be found on the <a href=\"http://www.chw.org/medical-care/birthmarks-and-vascular-anomalies-center/conditions/phace-syndrome/phace-syndrome-registry&amp;token=i991aYQwCy+oKOuqFU1MH6gE2OfIJvUbL7jrLHg8dPLMoSSzM/Aomw4RSSAGzyu91ocJXqSEkfGtoVqdS/9nngAijruifz1Qf0/bcMkZToHmVSz7CSk9R+YoWCYGTTFF&amp;TOPIC_ID=5794\" target=\"_blank\" class=\"external\">Children's Hospital of Wisconsin</a> website.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Lumbosacral lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemangiomas located over the lumbar or sacral spine may be associated with myelopathy, spinal bony, <span class=\"nowrap\">and/or</span> genitourinary or anorectal anomalies [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/78-84\" class=\"abstract_t\">78-84</a>]. Several acronyms have been proposed to describe the association of segmental lower-body hemangiomas with underlying developmental abnormalities, including LUMBAR (lower-body hemangioma and other cutaneous defects, urogenital anomalies, ulceration, myelopathy, bony deformities, anorectal malformations, arterial anomalies, and renal anomalies) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/82\" class=\"abstract_t\">82</a>]; PELVIS (perineal hemangioma, external genital malformations, lipomyelomeningocele, vesicorenal abnormalities, imperforate anus and skin tag) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/83\" class=\"abstract_t\">83</a>]; and SACRAL (spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/84\" class=\"abstract_t\">84</a>].</p><p>Localized lesions that are adjacent to but do not cross the midline usually do not warrant further evaluation [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/85\" class=\"abstract_t\">85</a>]. In contrast, segmental lesions that span the midline over the gluteal cleft and lumbosacral spine (<a href=\"image.htm?imageKey=PEDS%2F72298\" class=\"graphic graphic_picture graphicRef72298 \">picture 9</a>) are of greatest concern and should undergo MRI as part of their evaluation [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/83\" class=\"abstract_t\">83</a>]. The evaluation of children with these lesions is discussed separately. (See <a href=\"topic.htm?path=infantile-hemangiomas-evaluation-and-diagnosis#H11\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Evaluation and diagnosis&quot;, section on 'Lumbosacral'</a>.)</p><p class=\"headingAnchor\" id=\"H83438641\"><span class=\"h3\">Acral lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 18 percent of infantile hemangiomas occur on the extremities [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/5\" class=\"abstract_t\">5</a>]. The majority of larger hemangiomas in this location exhibit a &quot;biker-glove&quot; distribution, which describes hemangiomas that extend on the digits, sparing the distal tips, and often maintain a contiguous border across digits when the fingers or toes are approximated (<a href=\"image.htm?imageKey=DERM%2F96787\" class=\"graphic graphic_picture graphicRef96787 \">picture 10</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/86\" class=\"abstract_t\">86</a>]. These lesions often demonstrate a reticular morphology with minimal or arrested growth and may be complicated by ulceration.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Other associations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to PHACE syndrome, spinal dysraphism, and genitourinary anomalies, solitary, segmental hemangiomas of the skin may be associated with visceral hemangiomas. Similar to the aforementioned associations, in such cases, visceral hemangiomas tend to be regional to their cutaneous counterparts [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/87\" class=\"abstract_t\">87</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Multiple lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most children with multiple hemangiomas (arbitrarily defined as &ge;5 generally small, localized hemangiomas), the hemangiomas are limited to the skin, and the condition is benign (benign neonatal hemangiomatosis). Visceral (particularly hepatic) hemangiomas that cause life-threatening complications (also known as diffuse neonatal hemangiomatosis) appear to be rare.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Hepatic hemangiomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multifocal hepatic hemangiomas most commonly occur in the presence of multiple (&gt;5, with the risk increasing exponentially) skin hemangiomas and are probably most often asymptomatic, in which case they can be managed with observation with or without serial imaging.</p><p>Rarely, multifocal hepatic hemangiomas can have large vessel shunts that result in heart failure, which can be treated with pharmacotherapy or embolization if necessary. Diffuse liver hemangiomas, which may occur in the absence of skin hemangiomas, cause massive hepatomegaly with abdominal compartment syndrome, impaired ventilation, impaired venous return, and renal vein compression, and are associated with a high mortality rate [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/88\" class=\"abstract_t\">88</a>].</p><p>Other rare potential complications of visceral hemangiomas, dependent on specific organ involvement, include gastrointestinal hemorrhage, obstructive jaundice, and central nervous system sequelae due to mass effects [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/89-91\" class=\"abstract_t\">89-91</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cutaneous hemangiomas are uncomplicated and require no intervention. However, some lesions may ulcerate, leading to pain, bleeding, scarring, <span class=\"nowrap\">and/or</span> infection. Other lesions may cause functional impairment during, <span class=\"nowrap\">and/or</span> disfigurement after, the proliferative phase (<a href=\"image.htm?imageKey=DERM%2F50196\" class=\"graphic graphic_table graphicRef50196 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Ulceration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ulceration is the most common complication of hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/16\" class=\"abstract_t\">16</a>]. In a prospective cohort of 1096 children (&lt;12 years) with infantile hemangiomas, ulceration occurred in approximately 16 percent [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/92\" class=\"abstract_t\">92</a>]. It is particularly frequent when hemangiomas are rapidly proliferating and located in trauma- or pressure-prone locations (<a href=\"image.htm?imageKey=PEDS%2F74768%7EPEDS%2F68162\" class=\"graphic graphic_picture graphicRef74768 graphicRef68162 \">picture 11A-B</a>) [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/92\" class=\"abstract_t\">92</a>]. An early white discoloration of the hemangioma surface in infants younger than three months may herald ulceration [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/52\" class=\"abstract_t\">52</a>]. The cause of ulcer formation is unknown, but given the typical locations, maceration and frictional stress are probable contributing factors [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/93\" class=\"abstract_t\">93</a>]. Ulceration is often painful and may lead to bleeding, infection, and, invariably, scarring. The management of ulcerated hemangiomas is discussed separately. </p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although a common concern among parents, bleeding is rarely profuse and can generally be stopped with application of direct pressure.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Airway hemangiomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Airway hemangiomas can develop in children who do not have cutaneous hemangiomas. However, the risk of airway hemangioma is higher with segmental hemangiomas located in a cervicofacial, mandibular, or &quot;beard&quot; distribution, which may include all or some of the following: the preauricular skin, mandible, lower lip, chin, or anterior neck (<a href=\"image.htm?imageKey=PEDS%2F58168\" class=\"graphic graphic_picture graphicRef58168 \">picture 12</a>).</p><p>The possibility of airway hemangioma must be considered in any child who has a cutaneous hemangioma in a cervicofacial mandibular distribution and develops progressive hoarseness or stridor. Affected infants are most likely to experience symptoms between the ages of 6 and 12 weeks, when hemangioma proliferation is most rapid. Symptoms may progress from initial hoarseness or stridor to respiratory failure. Cough and cyanosis are other common manifestations. Airway involvement can be confirmed using endoscopic visualization [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/94\" class=\"abstract_t\">94</a>]. The management of airway hemangiomas is discussed separately. (See <a href=\"topic.htm?path=infantile-hemangiomas-management\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Periorbital hemangiomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Periorbital hemangiomas may compromise normal visual development [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/95\" class=\"abstract_t\">95</a>]. The majority of hemangiomas that lead to visual complications involve the upper medial eyelid. However, a hemangioma of any size or morphology in the periorbital location may pose a threat to vision (<a href=\"image.htm?imageKey=DERM%2F50631\" class=\"graphic graphic_picture graphicRef50631 \">picture 13</a>). Subcutaneous periocular hemangiomas are of particular concern since they may extend deep into the orbit, causing exophthalmos or globe displacement with only subtle cutaneous manifestations [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/95\" class=\"abstract_t\">95</a>].</p><p>Astigmatism, the most common complication, results from direct pressure of the growing hemangioma on the cornea. Other potential problems include ptosis, proptosis, and strabismus. Stimulus-deprivation amblyopia, a result of physical obstruction of the visual axis by a hemangioma, is one of the leading causes of preventable blindness in children. Astigmatism, strabismus, and amblyopia are discussed separately. (See <a href=\"topic.htm?path=evaluation-and-management-of-strabismus-in-children\" class=\"medical medical_review\">&quot;Evaluation and management of strabismus in children&quot;</a> and <a href=\"topic.htm?path=amblyopia-in-children-classification-screening-and-evaluation#H3240702\" class=\"medical medical_review\">&quot;Amblyopia in children: Classification, screening, and evaluation&quot;, section on 'Deprivational amblyopia'</a>.)</p><p>Early examination by an ophthalmologist familiar with periorbital hemangiomas and their potential complications is mandatory, since prolonged, severe visual compromise can result in permanent damage, including blindness. The management of periorbital hemangiomas is discussed separately. (See <a href=\"topic.htm?path=infantile-hemangiomas-management\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Other hemangiomas</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas of the ear may obstruct the auditory canal, leading to otitis externa [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/96\" class=\"abstract_t\">96</a>]. Sensorineural hearing loss does not occur except in the very rare case of bilateral obstruction.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas of the tongue, oral cavity, or aerodigestive tract may rarely interfere with eating, swallowing, or speech [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/14,15,96\" class=\"abstract_t\">14,15,96</a>]. Lesions in these locations that are significant enough to cause complications are much more often vascular malformations, not hemangiomas.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nuchal hemangiomas may temporarily impair range of motion of the neck.</p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Kasabach-Merritt phenomenon</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Severe thrombocytopenia <span class=\"nowrap\">and/or</span> coagulopathy that results from platelet trapping within a vascular tumor is called the Kasabach-Merritt phenomenon. Although children with large common hemangiomas were once thought to be at risk for this complication, the Kasabach-Merritt phenomenon is now known to be associated with two other types of vascular tumors: kaposiform hemangioendothelioma and tufted angioma, and is not associated with true infantile hemangiomas [<a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/97,98\" class=\"abstract_t\">97,98</a>]. (See <a href=\"topic.htm?path=tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon\" class=\"medical medical_review\">&quot;Tufted angioma, kaposiform hemangioendothelioma, and the Kasabach-Merritt phenomenon&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=hemangioma-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Hemangioma (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infantile hemangiomas are the most common vascular tumors in infants and children. They are more common in girls than boys and among white non-Hispanic infants than among those of other <span class=\"nowrap\">racial/ethnic</span> groups. The incidence is increased in preterm infants. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The majority of hemangiomas are not clinically evident at birth but become apparent within the first days to months of life. Hemangiomas have a predilection for the head and neck, although they can occur anywhere in the skin, mucous membranes, or internal organs. They range in size from a few millimeters to many centimeters in diameter. They may be superficial, deep, or combined. (See <a href=\"#H6\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas characteristically undergo a growth (proliferative) phase that is generally most rapid for the first several months. The proliferative phase is followed by a spontaneous involution phase that typically begins after one year and lasts a variable number of years. (See <a href=\"#H7\" class=\"local\">'Natural history'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiomas can be categorized as localized (or focal), segmental, or multiple:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Localized hemangiomas demonstrate clear, well-defined spatial containment, appear to arise from a single focus, and lack evidence of a linear or geometric pattern. (See <a href=\"#H8\" class=\"local\">'Localized lesions'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Segmental hemangiomas are usually plaque-like and demonstrate a linear <span class=\"nowrap\">and/or</span> geographic presence over a specific cutaneous territory (<a href=\"image.htm?imageKey=PEDS%2F82212\" class=\"graphic graphic_picture graphicRef82212 \">picture 7</a>). (See <a href=\"#H9\" class=\"local\">'Segmental lesions'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Multiple hemangiomas are arbitrarily defined as &ge;5 generally small, localized hemangiomas. (See <a href=\"#H13\" class=\"local\">'Multiple lesions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most cutaneous hemangiomas are uncomplicated and require no intervention. However, some lesions may ulcerate, leading to pain, bleeding, scarring, <span class=\"nowrap\">and/or</span> infection. Other lesions may cause functional impairment during, <span class=\"nowrap\">and/or</span> disfigurement after, the proliferative phase (<a href=\"image.htm?imageKey=DERM%2F50196\" class=\"graphic graphic_table graphicRef50196 \">table 2</a>). (See <a href=\"#H15\" class=\"local\">'Complications'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/1\" class=\"nounderline abstract_t\">Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997; 13:375.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/2\" class=\"nounderline abstract_t\">L&eacute;aut&eacute;-Labr&egrave;ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 390:85.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/3\" class=\"nounderline abstract_t\">Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003; 48:477.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/4\" class=\"nounderline abstract_t\">Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 2004; 50:875.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/5\" class=\"nounderline abstract_t\">Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118:882.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/6\" class=\"nounderline abstract_t\">Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25:168.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/7\" class=\"nounderline abstract_t\">Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics 1976; 58:218.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/8\" class=\"nounderline abstract_t\">Alper JC, Holmes LB. The incidence and significance of birthmarks in a cohort of 4,641 newborns. Pediatr Dermatol 1983; 1:58.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/9\" class=\"nounderline abstract_t\">Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 2014; 170:907.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/10\" class=\"nounderline abstract_t\">PRATT AG. Birthmarks in infants. AMA Arch Derm Syphilol 1953; 67:302.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/11\" class=\"nounderline abstract_t\">JACOBS AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med 1957; 86:8.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/12\" class=\"nounderline abstract_t\">Blei F, Walter J, Orlow SJ, Marchuk DA. Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 1998; 134:718.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/13\" class=\"nounderline abstract_t\">Castr&eacute;n E, Salminen P, Vikkula M, et al. Inheritance Patterns of Infantile Hemangioma. Pediatrics 2016; 138.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/14\" class=\"nounderline abstract_t\">Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002; 138:1567.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/15\" class=\"nounderline abstract_t\">Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341:173.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/16\" class=\"nounderline abstract_t\">Hemangioma Investigator Group, Haggstrom AN, Drolet BA, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150:291.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/17\" class=\"nounderline abstract_t\">Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol 1997; 14:173.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/18\" class=\"nounderline abstract_t\">Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg 1983; 18:894.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/19\" class=\"nounderline abstract_t\">Colonna V, Resta L, Napoli A, Bonifazi E. Placental hypoxia and neonatal haemangioma: clinical and histological observations. Br J Dermatol 2010; 162:208.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/20\" class=\"nounderline abstract_t\">de Jong S, Itinteang T, Withers AH, et al. Does hypoxia play a role in infantile hemangioma? Arch Dermatol Res 2016; 308:219.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/21\" class=\"nounderline abstract_t\">Ritter MR, Dorrell MI, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 2002; 99:7455.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/22\" class=\"nounderline abstract_t\">Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Arch Dermatol 2010; 146:1295.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/23\" class=\"nounderline abstract_t\">Leon-Villapalos J, Wolfe K, Kangesu L. GLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations. Br J Plast Surg 2005; 58:348.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/24\" class=\"nounderline abstract_t\">North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31:11.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/25\" class=\"nounderline abstract_t\">North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001; 137:559.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/26\" class=\"nounderline abstract_t\">Barn&eacute;s CM, Huang S, Kaipainen A, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A 2005; 102:19097.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/27\" class=\"nounderline abstract_t\">Yu Y, Fuhr J, Boye E, et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells 2006; 24:1605.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/28\" class=\"nounderline abstract_t\">Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107:745.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/29\" class=\"nounderline abstract_t\">Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002; 33:295.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/30\" class=\"nounderline abstract_t\">Nguyen VA, F&uuml;rhapter C, Romani N, et al. Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol 2004; 35:739.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/31\" class=\"nounderline abstract_t\">Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118:2592.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/32\" class=\"nounderline abstract_t\">Ritter MR, Reinisch J, Friedlander SF, Friedlander M. Myeloid cells in infantile hemangioma. Am J Pathol 2006; 168:621.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/33\" class=\"nounderline abstract_t\">Bielenberg DR, Bucana CD, Sanchez R, et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 1999; 14:401.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/34\" class=\"nounderline abstract_t\">Dadras SS, North PE, Bertoncini J, et al. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol 2004; 17:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/35\" class=\"nounderline abstract_t\">Nguyen VA, Kutzner H, F&uuml;rhapter C, et al. Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. Mod Pathol 2006; 19:291.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/36\" class=\"nounderline abstract_t\">Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103:1373.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/37\" class=\"nounderline abstract_t\">Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93:2357.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/38\" class=\"nounderline abstract_t\">Tan ST, Velickovic M, Ruger BM, Davis PF. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg 2000; 106:529.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/39\" class=\"nounderline abstract_t\">Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14:1236.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/40\" class=\"nounderline abstract_t\">Claesson-Welsh L. Healing hemangiomas. Nat Med 2008; 14:1147.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/41\" class=\"nounderline abstract_t\">Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997; 19:237.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/42\" class=\"nounderline abstract_t\">Razon MJ, Kr&auml;ling BM, Mulliken JB, Bischoff J. Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation 1998; 5:189.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/43\" class=\"nounderline abstract_t\">Ritter MR, Moreno SK, Dorrell MI, et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol 2003; 1:291.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/44\" class=\"nounderline abstract_t\">Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136:905.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/45\" class=\"nounderline abstract_t\">Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997; 37:631.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/46\" class=\"nounderline abstract_t\">Hand JL, Frieden IJ. Vascular birthmarks of infancy: resolving nosologic confusion. Am J Med Genet 2002; 108:257.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/47\" class=\"nounderline abstract_t\">Fishman SJ, Mulliken JB. Hemangiomas and vascular malformations of infancy and childhood. Pediatr Clin North Am 1993; 40:1177.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/48\" class=\"nounderline abstract_t\">Martinez-Perez D, Fein NA, Boon LM, Mulliken JB. Not all hemangiomas look like strawberries: uncommon presentations of the most common tumor of infancy. Pediatr Dermatol 1995; 12:1.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/49\" class=\"nounderline abstract_t\">Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/50\" class=\"nounderline abstract_t\">Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122:360.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/51\" class=\"nounderline abstract_t\">Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics 2012; 130:e314.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/52\" class=\"nounderline abstract_t\">Maguiness SM, Hoffman WY, McCalmont TH, Frieden IJ. Early white discoloration of infantile hemangioma: a sign of impending ulceration. Arch Dermatol 2010; 146:1235.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/53\" class=\"nounderline abstract_t\">Suh KY, Frieden IJ. Infantile hemangiomas with minimal or arrested growth: a retrospective case series. Arch Dermatol 2010; 146:971.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/54\" class=\"nounderline abstract_t\">Ma EH, Robertson SJ, Chow CW, Bekhor PS. Infantile Hemangioma with Minimal or Arrested Growth: Further Observations on Clinical and Histopathologic Findings of this Unique but Underrecognized Entity. Pediatr Dermatol 2017; 34:64.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/55\" class=\"nounderline abstract_t\">Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006; 117:698.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/56\" class=\"nounderline abstract_t\">Waner M, North PE, Scherer KA, et al. The nonrandom distribution of facial hemangiomas. Arch Dermatol 2003; 139:869.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/57\" class=\"nounderline abstract_t\">Metry DW, Garzon MC, Drolet BA, et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol 2009; 26:381.</a></li><li class=\"breakAll\">PHACE Association. Online Mendelian Inheritance in Man (OMIM) website. OMIM entry #606519. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (Accessed on January 18, 2006).</li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/59\" class=\"nounderline abstract_t\">Frieden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996; 132:307.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/60\" class=\"nounderline abstract_t\">Metry D, Heyer G, Hess C, et al. Consensus Statement on Diagnostic Criteria for PHACE Syndrome. Pediatrics 2009; 124:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/61\" class=\"nounderline abstract_t\">Metry DW, Haggstrom AN, Drolet BA, et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet A 2006; 140:975.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/62\" class=\"nounderline abstract_t\">Opitz JM, Gilbert EF. CNS anomalies and the midline as a &quot;developmental field&quot;. Am J Med Genet 1982; 12:443.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/63\" class=\"nounderline abstract_t\">Bhattacharya JJ, Luo CB, Alvarez H, et al. PHACES syndrome: a review of eight previously unreported cases with late arterial occlusions. Neuroradiology 2004; 46:227.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/64\" class=\"nounderline abstract_t\">Metry DW, Dowd CF, Barkovich AJ, Frieden IJ. The many faces of PHACE syndrome. J Pediatr 2001; 139:117.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/65\" class=\"nounderline abstract_t\">Haggstrom AN, Garzon MC, Baselga E, et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics 2010; 126:e418.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/66\" class=\"nounderline abstract_t\">Pascual-Castroviejo I. Vascular and nonvascular intracranial malformation associated with external capillary hemangiomas. Neuroradiology 1978; 16:82.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/67\" class=\"nounderline abstract_t\">Pascual-Castroviejo I, Velez A, Pascual-Pascual SI, et al. Dandy-Walker malformation: analysis of 38 cases. Childs Nerv Syst 1991; 7:88.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/68\" class=\"nounderline abstract_t\">Poindexter G, Metry DW, Barkovich AJ, Frieden IJ. PHACE syndrome with intracerebral hemangiomas, heterotopia, and endocrine dysfunction. Pediatr Neurol 2007; 36:402.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/69\" class=\"nounderline abstract_t\">Burrows PE, Robertson RL, Mulliken JB, et al. Cerebral vasculopathy and neurologic sequelae in infants with cervicofacial hemangioma: report of eight patients. Radiology 1998; 207:601.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/70\" class=\"nounderline abstract_t\">Drolet BA, Dohil M, Golomb MR, et al. Early stroke and cerebral vasculopathy in children with facial hemangiomas and PHACE association. Pediatrics 2006; 117:959.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/71\" class=\"nounderline abstract_t\">Heyer GL, Dowling MM, Licht DJ, et al. The cerebral vasculopathy of PHACES syndrome. Stroke 2008; 39:308.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/72\" class=\"nounderline abstract_t\">Hess CP, Fullerton HJ, Metry DW, et al. Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome. AJNR Am J Neuroradiol 2010; 31:1980.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/73\" class=\"nounderline abstract_t\">Reese V, Frieden IJ, Paller AS, et al. Association of facial hemangiomas with Dandy-Walker and other posterior fossa malformations. J Pediatr 1993; 122:379.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/74\" class=\"nounderline abstract_t\">Martin KL, Arvedson JC, Bayer ML, et al. Risk of dysphagia and speech and language delay in PHACE syndrome. Pediatr Dermatol 2015; 32:64.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/75\" class=\"nounderline abstract_t\">Chiu YE, Siegel DH, Drolet BA, Hodgson BD. Tooth enamel hypoplasia in PHACE syndrome. Pediatr Dermatol 2014; 31:455.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/76\" class=\"nounderline abstract_t\">Duffy KJ, Runge-Samuelson C, Bayer ML, et al. Association of hearing loss with PHACE syndrome. Arch Dermatol 2010; 146:1391.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/77\" class=\"nounderline abstract_t\">Yu J, Siegel DH, Drolet BA, et al. Prevalence and Clinical Characteristics of Headaches in PHACE Syndrome. J Child Neurol 2016; 31:468.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/78\" class=\"nounderline abstract_t\">McAtee-Smith J, Hebert AA, Rapini RP, Goldberg NS. Skin lesions of the spinal axis and spinal dysraphism. Fifteen cases and a review of the literature. Arch Pediatr Adolesc Med 1994; 148:740.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/79\" class=\"nounderline abstract_t\">Goldberg NS, Hebert AA, Esterly NB. Sacral hemangiomas and multiple congenital abnormalities. Arch Dermatol 1986; 122:684.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/80\" class=\"nounderline abstract_t\">Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics 1989; 83:977.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/81\" class=\"nounderline abstract_t\">Tubbs RS, Wellons JC 3rd, Iskandar BJ, Oakes WJ. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg 2004; 100:86.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/82\" class=\"nounderline abstract_t\">Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr 2010; 157:795.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/83\" class=\"nounderline abstract_t\">Girard C, Bigorre M, Guillot B, Bessis D. PELVIS Syndrome. Arch Dermatol 2006; 142:884.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/84\" class=\"nounderline abstract_t\">Stockman A, Boralevi F, Ta&iuml;eb A, L&eacute;aut&eacute;-Labr&egrave;ze C. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 2007; 214:40.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/85\" class=\"nounderline abstract_t\">Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr 2010; 157:789.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/86\" class=\"nounderline abstract_t\">Weitz NA, Bayer ML, Baselga E, et al. The &quot;biker-glove&quot; pattern of segmental infantile hemangiomas on the hands and feet. J Am Acad Dermatol 2014; 71:542.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/87\" class=\"nounderline abstract_t\">Metry DW, Hawrot A, Altman C, Frieden IJ. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol 2004; 140:591.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/88\" class=\"nounderline abstract_t\">Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 2007; 42:62.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/89\" class=\"nounderline abstract_t\">Lopriore E, Markhorst DG. Diffuse neonatal haemangiomatosis: new views on diagnostic criteria and prognosis. Acta Paediatr 1999; 88:93.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/90\" class=\"nounderline abstract_t\">Boon LM, Burrows PE, Paltiel HJ, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. J Pediatr 1996; 129:346.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/91\" class=\"nounderline abstract_t\">Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005; 22:383.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/92\" class=\"nounderline abstract_t\">Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007; 151:684.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/93\" class=\"nounderline abstract_t\">Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44:962.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/94\" class=\"nounderline abstract_t\">Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a &quot;beard&quot; distribution. J Pediatr 1997; 131:643.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/95\" class=\"nounderline abstract_t\">Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21:1.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/96\" class=\"nounderline abstract_t\">Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001; 27:475.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/97\" class=\"nounderline abstract_t\">Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have &quot;true&quot; hemangiomas. J Pediatr 1997; 130:631.</a></li><li><a href=\"https://www.uptodate.com/contents/infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications/abstract/98\" class=\"nounderline abstract_t\">Osio A, Fraitag S, Hadj-Rabia S, et al. Clinical spectrum of tufted angiomas in childhood: a report of 13 cases and a review of the literature. Arch Dermatol 2010; 146:758.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5794 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Proliferation</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Involution</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL FEATURES</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Natural history</a><ul><li><a href=\"#H5833753\" id=\"outline-link-H5833753\">- Proliferation and involution</a></li><li><a href=\"#H3163479\" id=\"outline-link-H3163479\">- Infantile hemangiomas with minimal or arrested growth</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">Localized lesions</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Segmental lesions</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- PHACE syndrome</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Lumbosacral lesions</a></li><li><a href=\"#H83438641\" id=\"outline-link-H83438641\">- Acral lesions</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Other associations</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">Multiple lesions</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Hepatic hemangiomas</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">COMPLICATIONS</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Ulceration</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Bleeding</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Airway hemangiomas</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Periorbital hemangiomas</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Other hemangiomas</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Kasabach-Merritt phenomenon</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H367178141\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/5794|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/64171\" class=\"graphic graphic_figure\">- Pathogenesis hemangioma</a></li></ul></li><li><div id=\"DERM/5794|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/89391\" class=\"graphic graphic_picture\">- Infantile hemangioma precursor</a></li><li><a href=\"image.htm?imageKey=PEDS/60004\" class=\"graphic graphic_picture\">- Superficial hemangioma</a></li><li><a href=\"image.htm?imageKey=PEDS/50388\" class=\"graphic graphic_picture\">- Deep hemangioma</a></li><li><a href=\"image.htm?imageKey=DERM/61868\" class=\"graphic graphic_picture\">- Hemangioma sharp margins</a></li><li><a href=\"image.htm?imageKey=PEDS/60003\" class=\"graphic graphic_picture\">- Lip hemangioma</a></li><li><a href=\"image.htm?imageKey=DERM/65721\" class=\"graphic graphic_picture\">- Infantile hemangioma - arrested growth</a></li><li><a href=\"image.htm?imageKey=PEDS/82212\" class=\"graphic graphic_picture\">- Segmental hemangioma</a></li><li><a href=\"image.htm?imageKey=DERM/70599\" class=\"graphic graphic_picture\">- PHACE syndrome 1</a></li><li><a href=\"image.htm?imageKey=PEDS/72298\" class=\"graphic graphic_picture\">- Lumbosacral hemangioma</a></li><li><a href=\"image.htm?imageKey=DERM/96787\" class=\"graphic graphic_picture\">- Infantile hemangioma - biker glove</a></li><li><a href=\"image.htm?imageKey=PEDS/74768\" class=\"graphic graphic_picture\">- Ulcerated hemangioma perineum</a></li><li><a href=\"image.htm?imageKey=PEDS/68162\" class=\"graphic graphic_picture\">- Ulcerated hemangioma axilla</a></li><li><a href=\"image.htm?imageKey=PEDS/58168\" class=\"graphic graphic_picture\">- Beard distribution hemangioma</a></li><li><a href=\"image.htm?imageKey=DERM/50631\" class=\"graphic graphic_picture\">- Periocular hemangioma</a></li></ul></li><li><div id=\"DERM/5794|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/80245\" class=\"graphic graphic_table\">- PHACE syndrome</a></li><li><a href=\"image.htm?imageKey=DERM/50196\" class=\"graphic graphic_table\">- IH features morbidity</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=amblyopia-in-children-classification-screening-and-evaluation\" class=\"medical medical_review\">Amblyopia in children: Classification, screening, and evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">Capillary malformations (port wine stains) and associated syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-strabismus-in-children\" class=\"medical medical_review\">Evaluation and management of strabismus in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infantile-hemangiomas-evaluation-and-diagnosis\" class=\"medical medical_review\">Infantile hemangiomas: Evaluation and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infantile-hemangiomas-management\" class=\"medical medical_review\">Infantile hemangiomas: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemangioma-the-basics\" class=\"medical medical_basics\">Patient education: Hemangioma (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon\" class=\"medical medical_review\">Tufted angioma, kaposiform hemangioendothelioma, and the Kasabach-Merritt phenomenon</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vascular-lesions-in-the-newborn\" class=\"medical medical_review\">Vascular lesions in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-malformations\" class=\"medical medical_review\">Venous malformations</a></li></ul></div></div>","javascript":null}